Skip to main content
SpringerLink
Log in

Advances in Clinical Cardiology

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Multiple, potentially practice-changing cardiology trials have been presented or published over the past year. In this paper, we summarize and place in clinical context, new data regarding management of acute coronary syndrome and ST-elevation myocardial infarction (copeptin assessment, otamixaban, cangrelor, prasugrel, sodium nitrite, inclacumab, ranolazine, preventive coronary intervention of non-culprit lesions, immediate thrombolytic therapy versus transfer for primary intervention), new coronary intervention data (thrombectomy, radial access, pressure wire fractional flow reserve, antiplatelet therapy duration and gene-guidance, permanent and biodegradable polymers, coronary bifurcation and strategies), and coronary artery bypass data (off pump vs. on pump). Latest trials in trans-aortic valve implantation, heart failure (eplerenone, aliskiren, spironolactone, sildenafil, dopamine, nesiritide, omecamtiv mecarbil, the algisyl left ventricular augmentation device, and echo-guided cardiac resynchronization), atrial fibrillation (edoxaban, dabigatran, and ablation), cardiac arrest (hypothermia, LUCAS™ mechanical chest compression), and cardiovascular prevention (vitamins, renal denervation for resistant hypertension, renal artery stenting, saxagliptin, alogliptin, and gastric banding) are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Moeckel M, Searle J, Hamm C, et al. Biomarkers in Cardiology-8, (BIC-8). Instant early rule-out using cardiac troponin and copeptin in low-to medium-risk patients with suspected ACS: a prospective, randomised, multicentre study for early discharge. Presented at the European Society of Cardiology 2013 Congress, 3rd Sept 2013; Amsterdam, Netherlands.

  2. Steg P, Mehta SR, Pollack CV Jr, et al. Anticoagulation with otamixaban and ischaemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA. 2013;310(11):1145–55.

    Article  CAS  PubMed  Google Scholar 

  3. Steg G, Bhatt D, Hamm C. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981–92.

    Article  CAS  PubMed  Google Scholar 

  4. Wald D, Morris J, Wald N, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115–23.

    Article  CAS  PubMed  Google Scholar 

  5. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999–1010.

    Article  CAS  PubMed  Google Scholar 

  6. Armstrong P, Gershlick, Van de Werf F, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;368:1379–87.

  7. Siddiqi N. The nitrites in acute myocardial infarction (NIAMI) trial. In: Presented at the American Heart Association Scientific Sessions, 7th Nov 2013; Dallas, Texas, USA.

  8. Tardif J, Tanguay J, Wright SS, et al. Effects of the P-Selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61(20):2048–55.

    Article  CAS  PubMed  Google Scholar 

  9. Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038–45.

    Article  CAS  PubMed  Google Scholar 

  10. Chevalier B, Montalescot G, Belle L. Genotyping infarct patients to adjust and normalize thienopyridine treatment (GIANT). In: Presented at transcatheter cardiovascular therapeutics (TCT), 31st Oct 2013; San Francisco, United States of America.

  11. Collet JP, Montalescot G. Double randomization of a monitoring adjusted antiplatelet treatment versus a common antiplatelet treatment for DES implantation, and interruption versus continuation of double antiplatelet therapy-GENE, (ARCTIC-GENE). In: Presented at the European Society of Cardiology 2013 Congress, 4th Sept 2013; Amsterdam, Netherlands.

  12. Fröbert O, Lagerqvist B, Olivecrona G, et al. Thrombus aspiration during ST-segment elevation myocardial infarction (TASTE). N Engl J Med. 2013;369:1587–97.

    Article  PubMed  Google Scholar 

  13. Hess CN, Rao SV, Kong DF, et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). Am Heart J. 2013;166(3):421–8.

    Article  PubMed  Google Scholar 

  14. Curzen N. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain (RIPCORD). In: Presented at EuroPCR, 23rd May, 2013; Paris, France.

  15. Feres F. OPTIMIzed duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE). In: Presented at TCT, 31st Oct 2013; San Francisco, United States of America.

  16. Tandjung K, Basalus MW, von Birgelen C, et al. DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population. Am Heart J. 2012;163(4):557–62.

    Article  PubMed  Google Scholar 

  17. Ruangaard B. Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity®(SORT-OUT VI). In: Presented at transcatheter cardiovascular therapeutics (TCT), 29th Oct 2013; San Francisco, United States of America.

  18. Windecker S. BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With Single de Novo Coronary Artery Lesions-II (BIOFLOW II). In: Presented at EuroPCR, 21st May 2013; Paris, France.

  19. Maeng M, Holm NR, Erglis A, et al. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll of Cardiol. 2013;62(1):30–4.

    Article  Google Scholar 

  20. Kumsars I, Niemelä M, Erglis A, et al. Nordic-baltic bifurcation study IV. In: Presented at TCT, 3th Oct 2014, San Francisco.

  21. Leon M. A prospective, randomized trial of a dedicated sidebranch stent vs. a provisional stent strategy in true coronary bifurcation lesions (TRYTON). In: Presented at transcatheter cardiovascular therapeutics (TCT), 30th Oct 2013, San Francisco, United States of America.

  22. Diegeler A, Börgermann J, Kappert U, et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med. 2013;368(13):1189–98.

    Article  CAS  PubMed  Google Scholar 

  23. Lamy A, Devereaux PJ, Prabhakaran D, et al. Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med. 2013;368(13):1179–88.

    Article  CAS  PubMed  Google Scholar 

  24. Popma J. Safety and efficacy study of the medtronic CoreValve® system in the treatment of symptomatic severe aortic stenosis in high risk and very high risk subjects who need aortic valve replacement. In: Presented at transcatheter cardiovascular therapeutics (TCT), 29th Oct 2013; San Francisco, United States of America.

  25. Meredith I. REPRISE II: A prospective registry study of transcatheter aortic valve replacement with a repositionable transcatheter heart valve in patients with severe aortic stenosis. In: Presented at transcatheter cardiovascular therapeutics (TCT), 31st Oct 2013; San Francisco, United States of America.

  26. Van de Werf F, Brueckmann M, Connolly S, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.

    Article  PubMed  Google Scholar 

  27. Montalescot G, Zannad F, Lopez de Sa E, et al. Early administration of eplerenone in patients with acute myocardial infarction without heart failure: results of the randomized, double-blind, placebo-controlled REMINDER Trial. American College of Cardiology 2013 Scientific Sessions March 2013.

  28. Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125–35.

    Article  CAS  PubMed  Google Scholar 

  29. Pfeffer MA. TOPCAT Investigators. Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). American Heart Association Scientific Sessions, Nov 2013.

  30. Redfield MM, Borlaug BA, Lewis GD, et al. Heart Failure Clinical Research Network. PhosphdiesteRasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5(5):653–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA. 2013;309(12):1268–77.

    Article  CAS  PubMed  Google Scholar 

  32. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE Acute Heart Failure Randomized Trial. JAMA. 2013;310(23):2533–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Teerlink JR, Felker GM, McMurray JJV, et al. ATOMIC-AHF: acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: results from ATOMIC-AHF. European Society of Cardiology (ESC) Congress, Sept 2013.

  34. Mann D, Sabbah H, Hinson A, et al. A multicentre randomized study assessing the efficacy of left ventricular augmentation with Algisyl-LVR in the treatment of advanced heart failure with ischaemic and non-ischaemic cardiomyopathy: interim results of the AUGMENT-HF Study. American Heart Association Scientific Sessions, Nov 2013.

  35. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.

    Article  CAS  PubMed  Google Scholar 

  36. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66–74.

    Article  CAS  PubMed  Google Scholar 

  37. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    Article  CAS  PubMed  Google Scholar 

  38. Atienza F. Radiofrequency catheter ablation of drivers vs. circumferential pulmonary vein isolation in patients with atrial fibrillation. In: Presented at: American Heart Association Scientific Sessions, Nov 2013.

  39. Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed-enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498–506.

    Article  CAS  PubMed  Google Scholar 

  40. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013;369(23):2197–206.

    Article  CAS  PubMed  Google Scholar 

  41. Rubertsson S, Lindgren E, Smekal D, et al. Mechanical chest compressions and simultaneous defibrillation vs conventional cardiopulmonary resuscitation in out-of-hospital cardiac arrest: the LINC randomized trial. JAMA. 2014;311:53–61.

    Article  CAS  PubMed  Google Scholar 

  42. Gitt AK, Juenger C, Smolka, et al. Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL goal achievement in statin-treated patients for secondary prevention: results of DYSIS. European Society of Cardiology Congress, Sept 2013.

  43. Gitt AK, Juenger C, Smolka W, Wood D. Impact of pay-for-performance (UK) versus budget restricted (Germany) reimbursement system on LDL-goal-achievement in statin-treated patients for secondary prevention: results of DYSIS. American Heart Association Scientific Sessions, Nov 2013.

  44. Lamas G, Boineau R, Goertz C, et al. Oral high-dose multivitamins and minerals after myocardial infarction a randomized trial. Ann Intern Med. 2013;159(12):797–805.

    PubMed  PubMed Central  Google Scholar 

  45. Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Scheinert D. Renal sympathetic denervation using a novel percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension. Interim analysis: REDUCE-HTN post-market study. In: Presented at: transcatheter cardiovascular therapeutics October 2013.

  47. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.

    Article  CAS  PubMed  Google Scholar 

  48. Böhm M. The global SYMPLICITY registry: safety and effectiveness of renal artery denervation in real world patients with uncontrolled hypertension. In: Presented at: American College of Cardiology/i2 Scientific Session; 30 March 2013; Washington, DC.

  49. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotid renal artery disease. N Engl J Med. 2014;370(1):13–22.

    Article  CAS  PubMed  Google Scholar 

  50. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

    Article  CAS  PubMed  Google Scholar 

  51. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

    Article  CAS  PubMed  Google Scholar 

  52. Heffron S, Singh A, Zagzag J, et al. Gastric banding resolves metabolic syndrome in obese subjects over five years follow-up. J Am Coll Cardiol. 2013;61.

Download references

Acknowledgments

No funding or sponsorship was received for this study or publication of this article. No writing assistance was utilized in the production of this manuscript. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Conflict of interest

AMcN and NMcA declare no conflict of interest. IM has received grants to the institution, lecture/consultancy honorarium, and conference sponsorship from Boston Scientific, Randox, Sanofi Aventis, Servier, Menarini, Biosensors, Astra Zeneca, Bayer, Boehringer Ingelheim, Daichii Sankyo, Eli Lilly, Bristol Myers Squibb, and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Compliance with ethics guidelines

The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Craigavon Cardiac Centre, Southern Trust, Northern Ireland, BT63 5QQ, UK

    Andrew H. McNeice, Neil M. McAleavey & Ian B. A. Menown

Authors
  1. Andrew H. McNeice
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil M. McAleavey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian B. A. Menown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian B. A. Menown.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 189 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McNeice, A.H., McAleavey, N.M. & Menown, I.B.A. Advances in Clinical Cardiology. Adv Ther 31, 837–860 (2014). https://doi.org/10.1007/s12325-014-0141-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-014-0141-9

Keywords

Search

Navigation